Article in Journal of human hypertension, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
5 authors.
Leah RethyDepartment of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Vincenzo B PolsinelliDivision of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Paul MuntnerDepartment of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Natalie A BelloDepartment of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Jordana B CohenRenal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. jco@pennmedicine.upenn.edu.ORCID http://orcid.org/0000-0003-4649-079X
Funding
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Scientific and Data Coordinating Center(SDCC) for the P*U01DK060990 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI FELDMAN, HAROLD I · 2001 to 2017
$50.1M
Continuation of the Coordinating Center for the Chronic Renal Insufficiency Cohort (CRIC) StudyU24DK060990 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Amanda Hyre Anderson, Laura M Dember · 2018 to 2026
$21.5M
Institutional Career Development CoreKL2TR001874 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GENKINGER, JEANINE M., SHIMBO, DAICHI · 2016 to 2025
$13.6M
Barber-Pharmacist Coordination to Improve Blood Pressure Management in Black MenR01HL117983 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI ALBERT, CHRISTINE M · 2014 to 2018
$8.6M
Incorporation of a Hypertension Working Group into the Jackson Heart StudyR01HL117323 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LEWIS, CORA E, OGEDEGBE, OLUGBENGA G. · 2013 to 2024
$7.2M
Promoting Academic Workforce Development in Behavioral Medicine and Sleep Disorders ResearchR25HL105444 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Girardin Jean-Louis, Tatjana Rundek · 2010 to 2026
$5.8M
Targeting Skeletal Muscle Perfusion and Oxidative Capacity in HFpEFR01HL155599 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI ZAMANI, PAYMAN · 2021 to 2025
$3.9M
Cardiovascular Risk, Vascular and Kidney Damage in COVID-19 SurvivorsR01HL157108 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI JULIO ALONSO CHIRINOS MEDINA, Jordana B. Cohen · 2022 to 2026
$3.9M
Multidrug Metabolic Approach to Improve Exercise and Skeletal Muscle Oxidative Capacity in HFpEFR01HL157264 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI ZAMANI, PAYMAN · 2021 to 2025
$3.5M
Informing optimal first-line antihypertensive therapy: A rigorous comparative effectiveness analysis of ARBs vs. ACEIs on long-term risk of dementia, cancer, heart disease, and quality of lifeR01AG074989 · NIA · UNIVERSITY OF PENNSYLVANIA · PI BRESS, ADAM P, COHEN, JORDANA B. · 2022 to 2025
$3.3M
Blockade of calcium channels and beta adrenergic receptors for physiologic abnormalities in heart failure with preserved ejection fraction (BLOCK HFpEF)R01HL153646 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI COHEN, JORDANA B. · 2020 to 2024
to the editorPostmenopausal women have a higher risk of hypertension compared with premenopausal women possibly related to increased endothelial dysfunction in the setting of lower levels of circulating estrogen. Using data from 660 women in the Jackson Heart Study (JHS), postmenopausal women had higher daytime, nighttime and 24 h systolic blood pressure variability (BPV) compared with premenopausal women, and higher nighttime systolic BPV was associated with higher endothlin-1 (a marker of endothelial dysfunction) in postmenopausal women (ß = 0.27 [0.05, 0.50], p = 0.019), even after adjustment for possible confounders including age. These findings highlight the relevance of menopause status to blood pressure variability and the potential role of blood pressure variability in the development of high endothelin-1 in postmenopausal women.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Association of blood pressure variability with Endothelin-1 by menopause status among Black women: findings from the Jackson Heart Study. · full record | OpenQuestion